Veterinarian examining dog with researcher analyzing tumor sample

Drug Discovery: Unlocking the Secrets of Anticancer Compounds Through Pets

Jordan Keane monogram
Jordan Keane in Health & Wellness November 2026 • 4 min read.

"Innovative research at the University of Illinois leverages comparative genomics and veterinary oncology to find new treatments for cancer in both animals and humans."


The fight against cancer is a relentless pursuit, with researchers constantly seeking innovative strategies to outsmart this complex disease. Traditional drug discovery methods can be time-consuming and costly, often facing challenges in translating preclinical success to effective human treatments. Now, a pioneering approach is emerging, harnessing the power of comparative oncology and the unique position of our beloved pets.

At the University of Illinois at Urbana-Champaign, a groundbreaking research theme, "Anticancer Discovery from Pets to People," is revolutionizing the field. This initiative brings together a multidisciplinary team of medicinal chemists, computational biologists, and veterinary oncologists to explore new avenues for anticancer drug development. Their innovative strategy focuses on leveraging companion animals with cancer as a means to identify novel anticancer compounds and targets.

This approach not only offers a compassionate way to treat pets suffering from cancer, but also serves as a valuable stepping stone towards human clinical trials. By studying naturally occurring cancers in pets, researchers gain unique insights into tumor biology and drug response, potentially accelerating the development of more effective and personalized cancer therapies for both animals and humans.

AI Search Multiple angles on this topic

The Veterinary Oncology Landscape

Veterinary oncology is a specialized segment of animal healthcare focused on diagnosing, treating, and managing cancer in companion animals, particularly dogs and cats. The field includes diagnostics and therapeutics, including cytotoxic chemotherapy drugs and targeted anticancer drugs. Treatment costs vary by intervention, from moderate diagnostic expenses to more costly chemotherapy, radiation, and targeted therapies.

From Screening to Clinical Relevance

Anticancer drug development commonly follows a continuum from in vitro drug screening toward eventual clinical relevance. Artificial intelligence is emerging as a transformative tool in oncology drug discovery, but its adoption is constrained by limited access to high-quality datasets, data-security and privacy concerns, and underdeveloped computational infrastructure. Veterinary drug-discovery reviews also emphasize omics-based tools for identifying disease-causing target genes or proteins, while veterinary oncology continues to balance advances with clinical and research limitations.

Why Pets? The Power of Comparative Oncology

Veterinarian examining dog with researcher analyzing tumor sample

The cornerstone of this research lies in the concept of comparative oncology, which recognizes the similarities between cancers in humans and animals. Companion animals, particularly dogs and cats, develop many of the same types of cancer as humans, including lymphoma, osteosarcoma, and melanoma. These cancers often share similar genetic and molecular characteristics, making pets valuable models for studying human cancer.

Moreover, cancers in pets often develop spontaneously in a natural environment, mimicking the way cancer arises in humans. This contrasts with traditional laboratory models, where cancer is often induced in animals. Studying naturally occurring cancers in pets can provide a more realistic understanding of the disease and its response to treatment.

  • Shared Biology: Many cancers in pets share genetic and molecular similarities with human cancers.
  • Natural Development: Cancers in pets develop spontaneously, mimicking the natural progression of the disease in humans.
  • Real-World Environment: Pets live in similar environments to humans, exposing them to comparable environmental factors that may influence cancer development and treatment response.
AI Search Multiple angles on this topic

Deep Learning and Drug Repurposing

Recent reviews describe deep learning as an important influence on anticancer drug design, although research specifically focused on anticancer development remains limited. Veterinary oncology research spans cancer biology, tumor pathogenesis, novel therapies, diagnostic techniques, and palliative care. Another review presents drug repurposing, the search for new therapeutic uses for existing medicines, as a potentially cost-effective and time-efficient alternative to developing drugs de novo.

The Translation Problem

Reviews of animal research report that rising drug-development costs and very high failure rates have prompted renewed evaluation of animal studies. A central concern is whether nonhuman animal models reliably predict human toxicity during preclinical pharmaceutical development. Other critiques point to the burden on patients and healthcare systems, the large numbers of animals used in research and testing, and the relatively high rate of translational failure.

Shared Cancer Questions Across Species

Comparative oncology examines cancer across humans and companion animals, including dogs and cats. Recent reviews compare cancer epidemiology, tumor biology, pharmacologic treatments, drug-formulation challenges, and regulatory considerations across these species. The literature also identifies opportunities for closer collaboration between human and veterinary clinics while noting challenges in applying comparative oncology to targeted-therapy development.

By studying cancer in pets, researchers can accelerate the drug discovery process. Clinical trials in pets can be conducted more quickly and efficiently than in humans, providing valuable data on drug efficacy and toxicity. Promising compounds can then be advanced to human clinical trials, increasing the likelihood of success.

A Personalized Approach to Cancer Treatment

The "Anticancer Discovery from Pets to People" theme embraces a precision medicine approach, tailoring cancer treatment to the individual characteristics of each patient. By analyzing the genetic and molecular profiles of tumors in both pets and humans, researchers can identify specific targets for drug therapy. This personalized approach aims to maximize treatment effectiveness while minimizing side effects.

AI Search Multiple angles on this topic

A Field Still Evolving

Expert Opinion on Drug Discovery continues to publish dedicated issues on drug-discovery research and commentary. Volume 19, Issue 10 was identified in 2024, while Volume 21, Issue 9 is listed as a 2026 current issue. Together, these issue records show an active publication forum for evaluating developments in drug discovery.

New Tools in Veterinary Oncology

Veterinary oncology is expanding across several fronts, including new drugs for mast cell tumors, chemotherapy-induced diarrhea, and lymphoma. Recent advances also include interventional radiology, stereotactic radiation, liquid biopsy, and veterinary clinical trials. Market commentary describes emerging technologies as reshaping how veterinary cancer treatments are developed and delivered.

Progress With Persistent Gaps

Veterinary oncology has changed substantially over the past decade through advances in molecular biology, imaging, therapeutics, and translational research. These developments have expanded diagnostic precision and therapeutic possibilities for companion animals with cancer. The field nevertheless continues to face significant challenges, and collaboration between general practitioners and veterinary oncologists is described as important for complex cases and client engagement.

Pets as Translational Partners

Comparative oncology studies naturally occurring cancers in companion animals, mainly dogs, and uses them as a tool in cancer research and drug development. Comparative oncology clinical trials can evaluate in vivo target modulation, drug tolerability, and pharmacokinetic-pharmacodynamic relationships relevant to human cancer research. Precision oncology platforms are also described as making advanced treatments more accessible to veterinarians without specialized oncology training or expensive equipment, with reported pricing comparable to conventional chemotherapy.

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

How does the "Anticancer Discovery from Pets to People" research theme at the University of Illinois aim to improve cancer treatment?

The "Anticancer Discovery from Pets to People" research theme at the University of Illinois employs a comparative oncology approach, leveraging naturally occurring cancers in pets to identify novel anticancer compounds and targets. By studying cancers that share genetic and molecular similarities with human cancers, researchers can accelerate the development of personalized cancer therapies for both animals and humans. This method facilitates quicker clinical trials and provides valuable data on drug efficacy and toxicity, ultimately aiming to translate findings into more effective and personalized treatments.

2

What is comparative oncology, and why is it crucial to the "Anticancer Discovery from Pets to People" initiative?

Comparative oncology is the study of similarities and differences between cancers in humans and animals. It's crucial to the "Anticancer Discovery from Pets to People" initiative because companion animals, like dogs and cats, develop cancers with similar genetic and molecular characteristics to those in humans. These naturally occurring cancers in pets develop in a real-world environment, mimicking how cancer arises in humans. This enables researchers to study cancer's progression and response to treatment more realistically. Also clinical trials can be conducted faster and more efficiently in pets.

3

In what ways can studying cancer in pets accelerate the anticancer drug discovery process?

Studying cancer in pets accelerates the anticancer drug discovery process because clinical trials can be conducted more quickly and efficiently than in humans. This provides faster access to valuable data on drug efficacy and toxicity. Since cancers in pets often share genetic and molecular similarities with human cancers and develop spontaneously in a natural environment, promising compounds can be advanced to human clinical trials with an increased likelihood of success. The research also encompasses precision medicine by analyzing genetic and molecular profiles to tailor treatment to individual characteristics.

4

How does the "Anticancer Discovery from Pets to People" theme incorporate precision medicine into its approach to cancer treatment?

The "Anticancer Discovery from Pets to People" theme embraces a precision medicine approach by tailoring cancer treatment to the individual characteristics of each patient. Researchers analyze the genetic and molecular profiles of tumors in both pets and humans to identify specific targets for drug therapy. This personalized approach aims to maximize treatment effectiveness while minimizing side effects. The missing aspect is a detailed example of how a particular genetic marker in pet tumors led to a breakthrough in human cancer treatment. Also, more details of the used drugs are necessary to explain how side effects are minimized.

5

What are the limitations of traditional drug discovery methods that the "Anticancer Discovery from Pets to People" initiative seeks to overcome?

Traditional drug discovery methods are often time-consuming and costly, with challenges in translating preclinical success to effective human treatments. Unlike the "Anticancer Discovery from Pets to People" initiative, traditional methods may not fully account for the complexities of cancer development in a natural environment, potentially leading to less effective therapies. The research uses comparative oncology and naturally occurring cancers in pets to bridge the gap between preclinical studies and human clinical trials. The initiative seeks to create precision medicine for humans.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.